
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation
Keywords: Janus kinase (JAK); JAK1; JAK2; Modified Glasgow prognostic score; Signal transducers and activators of transcription (STAT);